Chagas disease: State-of-the-art of diagnosis and management

Cardiology Journal

Volumn 15, Issue 6, 2008, Pages 493-504

  Dubner, Sérgio ^a   Schapachnik, Edgardo ^b   Pérez Riera, Andrés Ricardo ^c   Valero, Elina ^d  

^a Clinica y Maternidad Suizo Argentina   (Argentina)

^b HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^c FACULDADE DE MEDICINA DO ABC   (Brazil)

^d FLENI   (Argentina)

Author keywords

American trypnosomiasis; Chagas' disease; Diagnosis; Management

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTIPROTOZOAL AGENT; BENZNIDAZOLE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; PLACEBO; POSACONAZOLE; SPIRONOLACTONE;

ANTIFUNGAL ACTIVITY; ARTIFICIAL HEART PACEMAKER; CHAGAS DISEASE; CLINICAL TRIAL; DEFIBRILLATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ELECTROCARDIOGRAM; ENDEMIC DISEASE; HEART FAILURE; HEART MUSCLE INJURY; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FAILURE; HUMAN; INCUBATION TIME; LABORATORY TEST; MICROSCOPY; MORTALITY; NONHUMAN; PARASITE IDENTIFICATION; PARASITE TRANSMISSION; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SOUTH AND CENTRAL AMERICA; SPAIN; SWITZERLAND; THROMBOEMBOLISM; TRYPANOSOMA CRUZI; UNITED STATES; VECTORCARDIOGRAPHY; ZOONOSIS;

CARDIAC PACING, ARTIFICIAL; CARDIOVASCULAR AGENTS; CHAGAS DISEASE; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; HUMANS; QUALITY ASSURANCE, HEALTH CARE;

EID: 59849123911     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Puigbó JJ, Valecillos R, Hirschhaut E et al. Diagnosis of Chagas' cardiomyopathy. Non-invasive techniques. Postgrad Med J, 1977; 53: 527-532.
2. Elizari MV. Chagasic myocardiopathy: Historical perspective. Medicina (B Aires). 1999; 59 (suppl.) 2: 25-40.
3. Punukollu G, Gowda RM, Khan IA, Navarro VS, Vasavada BC. Clinical aspects of the Chagas' heart disease. Clinical aspects of the Chagas' heart disease. Int J Cardiol, 2007; 115: 279-283.
4. Bestetti RB, Soares EG, Sales-Neto VN, Oliveira JS. The ajmaline test as a method to disclose latent experimental Chagas' heart disease. Cardiovasc Drugs Ther, 1989; 3: 171-176.
5. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation, 2007; 115: 1109-1123.
6. James TN, Rossi MA, Yamamoto S. Postmortem studies of the intertruncal plexus and cardiac conduction system from patients with Chagas disease who died suddenly. Prog Cardiovasc Dis, 2005; 47: 258-275.
7. de Lima MA, Cabrine-Santos M, Tavares MG, Gerolin GP, Lages-Silva E, Ramirez LE. Interstitial cells of Cajal in chagasic megaesophagus. Ann Diagn Pathol, 2008; 12: 271-274.
8. Ribeiro AL, Rocha MO. Indeterminate form of Chagas disease: Considerations about diagnosis and prognosis. Rev Soc Bras Med Trop, 1998; 31: 301-314.
9. Abello M, González-Zuelgaray J, López C, Labadet C. Initiation modes of spontaneous monomorphic ventricular tachycardia in patients with Chagas heart disease Rev Esp Cardiol, 2008; 61: 487-493.
10. Carod-Artal FJ. Stroke: A neglected complication of American trypanosomiasis (Chagas' disease). Trans R Soc Trop Med Hyg, 2007; 101: 1075-1980.
11. Hotez PJ. Neglected infections of poverty in the United States of America. PLoS Negl Trop Dis, 2008; 2: e256.
12. Moraes-Souza H, Bordin JO. Strategies for prevention of transfusion-associated Chagas' disease. Transfus Med Rev, 1996; 10: 161-170.
13. Brutus L, Schneider D, Postigo J, Romero M, Santalla J, Chippaux JP. Congenital Chagas disease: Diagnostic and clinical aspects in an area without vectorial transmission, Bermejo, Bolivia. Acta Trop, 2008; 106: 195-159.
14. Ferreira CS, Martinho PC, Amato Neto V, Cruz RR. Pasteurization of human milk to prevent transmission of Chagas disease. Rev Inst Med Trop Sao Paulo, 2001; 43: 161-162.
15. Yoshida N. Trypanosoma cruzi infection by oral route: how the interplay between parasite and host components modulates infectivity. Parasitol Int, 2008; 57: 105-109.
16. Altclas JD, Barcan L, Nagel C, Lattes R, Riarte A. Organ transplantation and Chagas disease. JAMA, 2008; 299: 1134.
17. Centers for Disease Control and Prevention (CDC). Chagas disease after organ transplantation - United States, 2001. MMWR Morb Mortal Wkly Rep, 2002; 51: 210-212.
18. Nowicki MJ, Chinchilla C, Corado L et al. Prevalence of antibodies to Trypanosoma cruzi among solid organ donors in Southern California: A population at risk. Transplantation, 2006; 81:477-479.
19. Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin Microbiol Rev, 2001; 14: 659-688.
20. Moreira MC, Heringer-Walther S, Wessel N et al. Prognostic value of natriuretic peptides in Chagas' disease: A 3-year follow-up investigation. Cardiology, 2008; 110: 217-225.
21. Manzardo C, Trevińo B, Gómez Prat J et al. Communicable diseases in the immigrant population attended to in a tropical medicine unit: Epidemiological aspects and public health issues. Travel Med Infect Dis, 2008; 6: 4-11.
22. Herwaldt BL, Grijalva MJ, Newsome AL et al. Use of polymerase chain reaction to diagnose the fifth reported US case of autochthonous transmission of Trypansoma cruzi, in Tennessee, 1998. J Infect Dis, 2000; 181: 395-399.
23. Jackson Y, Chappuis F, Loutan L. Chagas disease in Switzerland: Managing an emerging infection and interrupting its transmission. Rev Med Suisse, 2008; 4: 1212-1214, 1216-1217.
24. Diez CN, Manattini S, Zanuttini JC, Bottasso O, Marcipar I. The value of molecular studies for the diagnosis of congenital Chagas disease in northeastern Argentina. Am J Trop Med Hyg, 2008; 78: 624-627.
25. Salles G, Xavier S, Sousa A, Hasslocher-Moreno A, Cardoso C. Prognostic value of QT interval parameters for mortality risk stratification in Chagas' disease: Results of a long-term follow-up study. Circulation, 2003; 108:305-312.
26. Corbucci HA, Haber DM, Bestetti RB, Cordeiro JA, Fioroni ML. QT interval dispersion in patients with chronic heart failure secondary to Chagas' cardiomyopathy: Correlation with clinical variables of prognostic significance. Cardiovasc Pathol, 2006; 15: 18-23.
27. Nunes Mdo C, Barbosa MM, Rocha MO. Peculiar aspects of cardiogenic embolism in patients with Chagas' cardiomyopathy: A transthoracic and transesophageal echocardiographic study. J Am Soc Echocardiogr, 2005; 18: 761-767.
28. Bocchi EA, Kalil R, Bacal F et al. Magnetic resonance imaging in chronic Chagas' disease: Correlation with endomyocardial biopsy findings and Gallium-67 cardiac uptake. Echocardiography, 1998; 15: 279-288.
29. Valente N, Pimenta J, Paola AA. Serial electrophysiological studies of the heart's excito conductor system in patients with chronic Chagasic cardiopathy. Arq Bras Cardiol, 2006; 86:19-25.
30. Bern C, Montgomery SP, Herwaldt BL et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA, 2007; 298: 2171-2181.
31. Altschüller MB, Pedrosa RC, Pereira B de B et al. Chronic Chagas disease patients with sinus node dysfunction: is the presence of IgG antibodies with muscarinic agonist action independent of left ventricular dysfunction? Rev Soc Bras Med Trop, 2007; 40: 665-671.
32. Riera AR, Uchida AH, Schapachnik E et al. The history of left septal fascicular block: Chronological considerations of a reality yet to be universally accepted. Indian Pacing Electrophysiol J, 2008; 8: 114-128.
33. Aranda Fraustro A, Chávez Rentería B, Ballinas Verdugo MA, Arce Fonseca M, Medrano Castro GA, de Micheli Serra A. Electro-histological comparison in a case of Chagasic chronic cardiomyopathy Arch Cardiol Mex, 2007;77:249-252.
34. Ribeiro AL, Cavalvanti PS, Lombardi F, Nunes Mdo C, Barros MV, Rocha MO. Prognostic value of signal-averaged electrocardiogram in Chagas disease. J Cardiovasc Electrophysiol, 2008; 19: 502-509.
35. Theodoropoulos TA, Bestetti RB, Otaviano AP, Cordeiro JA, Rodrigues VC, Silva AC. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy. Int J Cardiol, 2008; 128: 22-29.
36. Rassi A Jr, Rassi A, Little WC et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med, 2006; 355: 799-808.
37. Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: A systematic review of observational studies. Circulation, 2007; 115: 1101-1108.
38. Botoni FA, Poole-Wilson PA, Ribeiro AL et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J, 2007; 153: e1-e8.
39. Benaim G, Sanders JM, Garcia-Marchán Y et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem, 2006; 49: 892-829.
40. Leite LR, Fenelon G, Simoes A Jr, Silva GG, Friedman PA, de Paola AA. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. J Cardiovasc Electrophysiol, 2003; 14: 567-573.
41. Rassi A Jr, Rassi A, Little WC. Chagas' heart disease. Clin Cardiol, 2000; 23: 883-889.
42. Mora G, Echeverry MC, Rey GE, López MC, Posada LF, Rivas FA. Frequency of Trypanosoma cruzi infection in patients with implanted pacemaker. Biomedica, 2007; 27: 483-489.
43. Vanegas Cadavid DI. Marcapasos en la enfermedad de Chagas. Rev Latino Americana MCP y Arritmias 2008; 21: 70-76.
44. Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol, 2001; 76: 75-96.
45. Rincon LG, Rocha MO, Pires MT et al. Clinical profile of Chagas and non-Chagas' disease patients with cardiac pacemaker. Rev Soc Bras Med Trop, 2006; 39: 245-249.
46. de Lima CE, Martinelli Filho M, Silva RT et al. ICD patients with elevated defibrillation threshold: clinical behavior and therapeutic alternatives. Arq Bras Cardiol, 2008; 90: 160-166.
47. Cardinalli-Neto A, Greco OT, Bestetti RB. Automatic implantable cardioverter-defibrillators in Chagas' heart disease patients with malignant ventricular arrhythmias. Pacing Clin Electrophysiol, 2006; 29:467-470.
48. Dubner S, Valero E, Pesce R et al. Latin American registry of implantable cardioverter defibrillators: The ICD-LABOR study. Ann Noninvasive Electrocardiol, 2005; 10: 420-428.
49. Sosa E, Scanavacca M, d'Avila A, Oliveira F, Ramires JA. Non-surgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring late after myocardial infarction. J Am Coll Cardiol, 2000; 35: 1442-1449.
50. Sarabanda AV, Sosa E, Simões MV, Figueiredo GL, Pintya AO, Marin-Neto JA. Ventricular tachycardia in Chagas' disease: A comparison of clinical, angiographic, electrophysiologic and myocardial perfusion disturbances between patients presenting with either sustained or nonsustained forms. Int J Cardiol, 2005; 102: 9-19.
51. Sosa E, Scanavacca M, d'Avila A. Transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia. Curr Cardiol Rep, 2001; 3: 451-458.
52. Sosa E. Ablación Transcatéter de la Taquicardia Ventricular de Origen chagásico. Relampa, 2008; 21: 67-83.
53. Campos SV, Strabelli TM, Amato Neto V et al. Risk factors for Chagas' disease reactivation after heart transplantation. J Heart Lung Transplant, 2008; 27: 597-602.
54. Bacal F, Bocchi EA. Cardiac transplantation for Chagas' disease. Rev Insuf Cardíaca, 2008; 2: 85-87.